Entries by Qiqi Zhang

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

/1 Comment/in , /by

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

/in /by

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry March 7, 2024, Wuhan, China – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items […]

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

/1 Comment/in , /by

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine’s first-in-class monoclonal antibody drug, HMI-115. The first-in-class mAb will benefit endometriosis and androgenetic alopecia […]

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch

/in , /by

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the […]

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development

/in , /by

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. September 19, Wuhan, China […]

Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth

/in , /by

Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth The Hurun Research Institute recently released the Hurun Future Unicorns in the World 2023, and Chime Biologics was relisted among the Global Gazelle. Wuhan, China, August 17, 2023 – The Hurun Research Institute recently released the Hurun […]

Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally

/3 Comments/in , /by

Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials in China. BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications overseas and clinical trial materials Chime Biologics, […]